NMD Pharma, an Aarhus, Denmark-based clinical stage biotech company, raised €35M in funding.
The round was led by Jeito Capital with participation from INKEF Capital, Novo Holdings, Roche Venture Fund and Lundbeck Foundation. Jeito Capital has joined the NMD Pharma Board with Sabine Dandiguian, Managing Partner, as a Non-Executive Director.
The company intends to use the funds to advance its lead candidate, NMD670, through completion of the ongoing Phase 2a proof-of-concept trial in patients with Myasthenia Gravis and expand its clinical programs into several neuromuscular diseases. The financing will also support expansion of NMD Pharma’s discovery pipeline against novel targets, all focusing on the treatment of neuromuscular diseases.
Incorporated as a spin-off from Aarhus University, Denmark in 2015 and led by Thomas Holm Pedersen, Chief Executive Officer, NMD Pharma is a biotech company advancing novel first-in-class therapies for severe neuromuscular disorders. NMD has built a muscle electrophysiology platform leveraging the in-depth know-how of muscle physiology and muscular disorders, small molecule modulators, enabling technologies and tools as well as in-vivo pharmacology models for discovering and developing proprietary modulators of neuromuscular function.